Product Description
Gusacitinib (ASN002) is an orally bioavailable dual spleen tyrosine kinase (SYK)/pan Janus kinase (JAK) inhibitor that is being developed by Asana BioSciences. It is being evaluated for clinical efficacy in inflammatory and oncology settings. Not to be confused with Ascend Biopharmaceuticals immuno-oncology lead ASN-002, which is an engineered virus that expresses IFN-gamma . Gusacitinib is one of the chemical structures (example 189) claimed in Asana Biosciences' patent WO2013028818A1. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10000)
Mechanisms of Action: JAK2 Inhibitor, SYK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company Founding Year: 1973
Additional Commercial Interests: Formation Bio
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Basal Cell Carcinoma|Basal Cell Nevus Syndrome|Melanoma|Skin Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04416516 |
ASN-002-003 | P2 |
Completed |
Basal Cell Carcinoma|Basal Cell Nevus Syndrome |
2024-02-14 |
12% |
2024-04-11 |
|
ACTRN12619001298101 |
ASN-002-IL | P2 |
Not yet recruiting |
Basal Cell Nevus Syndrome|Skin Cancer|Basal Cell Carcinoma|Melanoma |
None |
2026-02-15 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/23/2025 |
News Article |
Libertas Bio, a Formation Bio subsidiary, License of Gusacitinib, a Dual JAK/SYK Inhibitor, to Sanofi |
|
09/19/2023 |
News Article |
Tyrosine Protein Kinase SYK Market Growth, Size, Share and Forecast [2030] |
|
09/01/2023 |
PubMed |
Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives. |
|
06/01/2023 |
PubMed |
Updated Review on Treatment of Atopic Dermatitis. |
|
05/23/2023 |
News Article |
TrialSpark Announces First Patient Dosed in Phase 2 Clinical Trial for ASN008-201 in Atopic Dermatitis |
|
11/29/2022 |
News Article |
TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio |